Telix Pharmaceuticals and AusHealth to Partner on Novel Therapeutics for Lung, Ovarian Cancer

Melbourne and Adelaide (Australia) – 30 October 2019. Telix Pharmaceuticals Limited has today announced that Telix and AusHealth have entered into a collaboration and technology licensing a

Melbourne and Adelaide (Australia) – 30 October 2019

Telix Pharmaceuticals Limited (ASX:TLX), has today announced that Telix and AusHealth have entered into a collaboration and technology licensing agreement for a novel Molecularly Targeted Radiation (MTR) platform called APOMAB®1 intended for the treatment of ovarian and lung cancers. The research behind the APOMAB technology was led by Professor Michael Brown at the Royal Adelaide Hospital (RAH) with support from AusHealth Research, a division of AusHealth.

To read the full media release click here.